Public Citizen seeks Crestor investigation
Executive Summary
Public Citizen calls for a criminal investigation of AstraZeneca "for illegally delaying the submission to the FDA of 23 reports of serious adverse reactions" for Crestor (rosuvastatin) in Aug. 3 letter to FDA. AstraZeneca maintains that rhabdomyolysis and acute renal failure are labeled events that do not require 15-day alert reports. Public Citizen filed a petition in March calling for Crestor's withdrawal (1"The Pink Sheet" May 24, 2004, p. 11)...
You may also be interested in...
AstraZeneca Defends Crestor; Public Citizen Renews Call For Withdrawal
The post-marketing safety profile of Crestor is in line with the overall experience of the statin category, AstraZeneca said May 19 in response to a renewed request from Public Citizen for withdrawal of the cholesterol-lowering drug
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.